Highland Capital Management (Texas)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Highland Capital Management (Texas)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$1.88M	Sell	6,020 -15,000	-71%	-$4.49M	0.11%	160
2019 Q1	$6.42M	Sell	21,020 -10,000	-32%	-$2.7M	0.4%	50
2018 Q4	$7.2M	Sell	31,020 -44,500	-59%	-$11.9M	0.55%	36
2018 Q3	$23.6M	Sell	75,520 -6,645	-8%	-$2.06M	1.3%	15
2018 Q2	$23.7M	Buy	82,165 +6,919	+9%	+$1.91M	1.35%	13
2018 Q1	$18.8M	Buy	75,246 +70,846	+1,610%	+$18M	0.97%	23
2017 Q4	$1.05M	Sell	4,400 -1,600	-27%	-$388K	0.05%	167
2017 Q3	$1.33M	Buy	+6,000	New	+$1.35M	0.06%	174
2017 Q2	–	Sell	-13,600	Closed	-$2.71M	–	293
2017 Q1	$2.71M	Sell	13,600 -13,700	-50%	-$2.64M	0.14%	134
2016 Q4	$4.98M	Sell	27,300 -35,700	-57%	-$6.09M	0.23%	104
2016 Q3	$10.3M	Buy	+63,000	New	+$9.56M	0.32%	66
2014 Q1	–	Sell	-5,270	Closed	-$651K	–	216
2013 Q4	$651K	Buy	5,270 +1,208	+30%	+$147K	0.04%	134
2013 Q3	$478K	Buy	+4,062	New	+$479K	0.03%	149

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Highland Capital Management (Texas)'s BIO Position: Q2 2019 in Review

Highland Capital Management (Texas) reduced its Bio-Rad Laboratories Class A (BIO) stake by 71% in Q2 2019, selling an estimated $4.49M and leaving 6,020 shares worth $1.88M. The position accounts for 0.11% of the portfolio, ranked #160.

Highland Capital Management (Texas) first reported a position in BIO in Q3 2013 and has held it in 13 quarters since. The position peaked at $23.7M in Q2 2018. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

Highland Capital Management (Texas) held 6,020 shares of Bio-Rad Laboratories Class A worth $1.88M as of Q2 2019.
Highland Capital Management (Texas) sold 15,000 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $4.49M.
Bio-Rad Laboratories Class A made up 0.11% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #160 holding.
Highland Capital Management (Texas) first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 13 quarters since.
Highland Capital Management (Texas)'s Bio-Rad Laboratories Class A position peaked at $23.7M in Q2 2018.
330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.